Fengshen Kuo

Fengshen Kuo

Auto-generated profile, based on publicly available information

Fengshen Kuo

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Cell
Verified
Journal Article
Closed access
NRNadeem Riaz
Nadeem Riaz
JHJonathan J. Havel
Jonathan J. Havel
VMVladimir Makarov
Vladimir Makarov
ADAlexis Desrichard
Alexis Desrichard
WUWalter J. Urba
Walter J. Urba
TCTimothy A. Chan
Timothy A. Chan

2 February 2018 in Science
Verified
Journal Article
Closed access
PDF file
DCDiego Chowell
Diego Chowell
LMLuc Morris
Luc Morris
CGClaud M. Grigg
Claud M. Grigg
JWJeffrey K. Weber
Jeffrey K. Weber
RSRobert M Samstein
Robert M Samstein
TCTimothy A. Chan
Timothy A. Chan
HLA genotype affects response: Immunotherapy works by activating the patient's own immune system to fight cancer. For effective tumor killing, CD8 + T cells recognize tumor peptides presented by human leukocyte antigen class I (HLA-I) molecules. In humans, there are three major HLA-I genes ( HLA-A, HLA-B , and HLA-C ). Chowell et al. asked whether germline HLA-I genotype influences how T cells recognize tumor peptides and respond to checkpoint inhibitor immunotherapies (see the Perspective by Kvistborg and Yewdell). They examined more than 1500 patients and found that heterozygosity at HLA-I loci was associated with better survival than homozygosity for one or more HLA-I genes. Thus, specific HLA-I mutations could have implications for immune recognition and for the design of epitopes for cancer vaccines and immunotherapies. Science , this issue p. 582 ; see also p. 516

3 May 2019 in Science
Verified
Journal Article
Closed access
PDF file
RMRajarsi Mandal
Rajarsi Mandal
RSRobert M Samstein
Robert M Samstein
KLKen-Wing Lee
Ken-Wing Lee
JHJonathan J. Havel
Jonathan J. Havel
HWHao Wang
Hao Wang
TCTimothy A. Chan
Timothy A. Chan
High mutational load gets a response: Cancers harbor many genetic mutations. Defects in DNA mismatch repair prevent tumors from repairing certain types of DNA damage and lead to a hypermutable genomic state known as microsatellite instability (MSI). Some tumors with a high degree of MSI may be treatable with PD-1 (programmed cell death–1) immunotherapy, but patient response is highly variable. Mandal et al. studied drivers of differential response to immunotherapy in these patients and found that MSI intensity and insertion-deletion mutations strongly affected therapeutic outcome. Science , this issue p. 485

15 April 2021 in Cancer Cell
Verified
Journal Article
Closed access
CKChirag Krishna
Chirag Krishna
RDRenzo G. DiNatale
Renzo G. DiNatale
FKFengshen Kuo
Fengshen Kuo
RSRaghvendra M. Srivastava
Raghvendra M. Srivastava
LVLynda Vuong
Lynda Vuong
AHAbraham Ari Hakimi
Abraham Ari Hakimi

22 April 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
WYWei Yang
Wei Yang
KLKen-Wing Lee
Ken-Wing Lee
RSRaghvendra M. Srivastava
Raghvendra M. Srivastava
FKFengshen Kuo
Fengshen Kuo
CKChirag Krishna
Chirag Krishna
LMLuc Morris
Luc Morris

7 November 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DCDiego Chowell
Diego Chowell
CKChirag Krishna
Chirag Krishna
FPFederica Pierini
Federica Pierini
VMVladimir Makarov
Vladimir Makarov
NRNaiyer A. Rizvi
Naiyer A. Rizvi
TCTimothy A. Chan
Timothy A. Chan